| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
Chief of Clinical Operations | Chief of Commerc. Operations | President, Commerc. Operations
1 company
Jodi Devlin is Chief of Clinical Operations at TLSI. Jodi Devlin's net worth is not public. Form 4 filings only show shares in the companies where this person is an insider; those holdings are worth an estimated $339K at current prices.
Historically, Jodi Devlin's trades have earned a middling insider score of 69/100 across 4 rated trades. Over a 12-month horizon, the one trade was profitable, with an average 12-month return of +39.2%.
The TLSI filings lean toward selling, a net 7,971 shares.
Jodi Devlin has 7 Form 4 filings on record from August 2023 to March 2026, all as Chief of Clinical Operations at TriSalus Life Sciences (TLSI), 2023–2026.
The 13 reported transactions were 5 stock awards, 4 open-market sales and 4 option or other derivative awards.
Counted by filing, the open-market trades come to no purchases and 2 sales worth about $38K.
The largest open-market sale was 4,764 shares of TLSI at an average $5.18 on May 19, 2025, about $25K. Twelve months later TLSI was down 39%.
Neither of the two sales since April 2023 was marked as made under a Rule 10b5-1 trading plan.